Michael Grass, PhD, is is head of Solid Form Services at Lonza Pharma & Biotech and was previously principal scientist at Capsugel’s Bend, Oregon facility.
Evaluating Drug Substance–Drug Product Interplay Accelerates Development
September 2nd 2020Innovative approaches to drug screening—such as evaluation to identify the optimal solid state of a molecule and in-vitro characterization to establish the optimal solid state of a molecule and the ideal bioavailability-enhancing technology—can help drug developers meet accelerated development timelines while managing risk.